Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.

Publikation

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.

Wissenschaftlicher Artikel/Review - 17.11.2021

Danese Silvio, Colombel Jean-Frédéric, Lukas Milan, Gisbert Javier P, D'Haens Geert, Hayee Bu'hussain, Panaccione Remo, Kim Hyun-Soo, Reinisch Walter, Tyrrell Helen, Oh Young S, Tole Swati, Chai Akiko, Chamberlain-James Kirsten, Tang Meina Tao, Schreiber Stefan, GARDENIA Study Group

Zitation

Danese S, Colombel J, Lukas M, Gisbert J, D'Haens G, Hayee B, Panaccione R, Kim H, Reinisch W, Tyrrell H, Oh Y, Tole S, Chai A, Chamberlain-James K, Tang M, Schreiber S, GARDENIA Study Group. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol 2021; 7:118-127.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Lancet Gastroenterol Hepatol 2021; 7

Veröffentlichungsdatum

17.11.2021

eISSN (Online)

2468-1253

Seiten

118-127

Kurzbeschreibung/Zielsetzung

Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to severely active ulcerative colitis. We aimed to compare the safety and efficacy of etrolizumab with infliximab in patients with moderately to severely active ulcerative colitis.